Silberbach M, Dunnigan A, Benson D W
Department of Pediatrics, Variety Club Children's Hospital, University of Minnesota, Minneapolis 55455.
Am J Cardiol. 1989 Feb 15;63(7):438-42. doi: 10.1016/0002-9149(89)90315-9.
The effects of intravenous verapamil (0.15 mg/kg) and propranolol (0.2 mg/kg) with regard to atrioventricular (AV) conduction and tachycardia termination during paroxysmal atrial tachycardia were compared in 2 groups of infants (verapamil n = 14, propranolol n = 18, mean age 80 +/- 21 days, range 1 to 364). Using transesophageal recording techniques, tachycardia cycle length, AV intervals and ventriculoatrial intervals were measured before and after drug administration. Both intravenous propranolol and verapamil significantly prolonged tachycardia cycle length and AV interval (cycle length--propranolol 230 +/- 30 to 262 +/- 33 ms, p less than 0.05, verapamil 223 +/- 38 to 245 +/- 32 ms, p less than 0.05; AV interval--propranolol 98 +/- 26 to 126 +/- 38 ms, p less than 0.05, verapamil 96 +/- 19 to 109 +/- 24 ms, p less than 0.05). Neither drug prolonged the ventriculoatrial interval. Tachycardia terminated after intravenous verapamil in 11 of 14 infants (79% efficacy rate). Tachycardia terminated in 0 of 18 after intravenous propranolol (0% efficacy rate). In 8 infants an atrial deflection was recorded on the esophageal electrocardiogram at the time of tachycardia termination after intravenous verapamil, which suggested that tachycardia terminated by block occurring in the AV node. In 2 infants a ventricular deflection was recorded at the time of tachycardia termination after verapamil, which suggested that block occurred in the accessory connection. Both drugs prolonged tachycardia cycle length by prolonging AV conduction to a similar degree.(ABSTRACT TRUNCATED AT 250 WORDS)
在两组婴儿中比较了静脉注射维拉帕米(0.15毫克/千克)和普萘洛尔(0.2毫克/千克)对阵发性房性心动过速期间房室(AV)传导和心动过速终止的影响(维拉帕米组n = 14,普萘洛尔组n = 18,平均年龄80±21天,范围1至364天)。使用经食管记录技术,在给药前后测量心动过速周期长度、AV间期和室房间期。静脉注射普萘洛尔和维拉帕米均显著延长心动过速周期长度和AV间期(周期长度——普萘洛尔从230±30毫秒延长至262±33毫秒,p<0.05,维拉帕米从223±38毫秒延长至245±32毫秒,p<0.05;AV间期——普萘洛尔从98±26毫秒延长至126±38毫秒,p<0.05,维拉帕米从96±19毫秒延长至109±24毫秒,p<0.05)。两种药物均未延长室房间期。14例婴儿中有11例在静脉注射维拉帕米后心动过速终止(有效率79%)。18例婴儿中静脉注射普萘洛尔后0例心动过速终止(有效率0%)。8例婴儿在静脉注射维拉帕米后心动过速终止时,食管心电图记录到心房波,提示心动过速通过AV结阻滞终止。2例婴儿在静脉注射维拉帕米后心动过速终止时记录到心室波,提示阻滞发生在旁道。两种药物通过延长AV传导,在相似程度上延长心动过速周期长度。(摘要截短至250字)